Ratings Tarsus Pharmaceuticals, Inc.

Equities

TARS

US87650L1035

Real-time Estimate Cboe BZX Other stock markets 15:07:09 2024-05-16 EDT			5-day change	1st Jan Change
38.54 ^USD	+0.09%		+13.19%	+90.27%

05-09	Oppenheimer Adjusts Tarsus Pharmaceuticals Price Target to $61 From $59, Maintains Outperform Rating	MT
05-08	Transcript : Tarsus Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 08, 2024

Summary

The company has a poor ESG score according to Refinitiv, which ranks companies by sector.

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
The company's "enterprise value to sales" ratio is among the highest in the world.
For the past year, analysts have significantly revised downwards their profit estimates.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
TARSUS PHARMACEUTICALS, INC.	+90.27%	1.45B	C-
ELI LILLY AND COMPANY	+32.94%	709B	C+
NOVO NORDISK A/S	+30.77%	595B	B
JOHNSON & JOHNSON	-1.79%	367B	C+
MERCK & CO., INC.	+20.22%	334B	B-
ABBVIE INC.	+5.93%	289B	C+
ASTRAZENECA PLC	+14.77%	239B	B+
NOVARTIS AG	+9.13%	211B	B-
ROCHE HOLDING AG	-3.97%	203B	A+
AMGEN INC.	+9.02%	171B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes